Does Mounjaro Get Rid of Belly Fat — and How Does It Work?

Does Mounjaro specifically target belly fat, or is that a myth?

A question our prescribers hear most weeks goes something like this: "I've been told Mounjaro melts belly fat, is that true?" The honest answer is that no medicine targets one fat depot and leaves others alone. Fat loss, whether driven by diet, exercise or a medicine like Mounjaro, happens across the body. What the evidence does show is that visceral fat (the deeper fat stored around the organs in your abdomen) tends to reduce proportionally, and often meaningfully, as overall body weight falls.

Visceral fat is not the same as the subcutaneous fat you can pinch. It sits behind the abdominal wall, wrapping around the liver, pancreas and gut, and it is more metabolically active than fat stored elsewhere. Because it turns over relatively quickly compared with, say, fat on the thighs, it often responds visibly to a sustained reduction in calorie intake. Tirzepatide works by activating two gut-hormone receptors (GIP and GLP-1) which reduce appetite and slow the rate at which the stomach empties. The result, for most people on treatment, is a lower overall calorie intake maintained over months. That sustained deficit is what drives abdominal fat loss, not any direct action on the belly itself. For a fuller look at the mechanism, the tirzepatide overview explains how both receptor pathways work.

So will Mounjaro get rid of belly fat? It can contribute to substantial reductions. The framing that it "melts" belly fat specifically overstates what the science shows; the reality (a clinically meaningful reduction in total body fat including visceral fat) is still significant.

What do the trial results actually show about waist and abdominal measurements?

The SURMOUNT-1 trial, published in the New England Journal of Medicine, enrolled adults with obesity and no diabetes and followed them for 72 weeks. At the 15 mg dose, participants lost an average of around 20–21% of their body weight. Waist circumference was measured as a secondary outcome throughout the trial, and it fell substantially alongside body weight, an expected finding, given that abdominal fat is a major component of excess weight in most participants.

Imaging studies in the wider tirzepatide programme have looked more closely at the split between visceral and subcutaneous fat. The consistent finding is that both types reduce, and visceral fat reduces in a way that tracks closely with the overall percentage of body weight lost. This matters clinically: visceral fat is associated with insulin resistance, raised triglycerides, and cardiovascular risk, so its reduction carries health benefits beyond aesthetics.

If you are weighing Mounjaro against semaglutide, tirzepatide and belly fat reduction is explored in more detail alongside the head-to-head data. The SURMOUNT-5 trial, published in 2025, found tirzepatide produced greater average weight loss than semaglutide 2.4 mg over 72 weeks, and where more total fat is lost, more abdominal fat typically follows. The NICE appraisal of tirzepatide (TA1026) drew on this evidence in recommending it for adults who meet the eligibility criteria.

Does the rate of belly fat loss change at higher Mounjaro doses?

Treatment starts at 2.5 mg, a dose whose job is to let your body adjust, not to drive weight loss. The prescriber then titrates upward, typically in four-week steps, through 5 mg, 7.5 mg, 10 mg, 12.5 mg and up to 15 mg. In trial data, the weight-loss effect (and by extension the abdominal fat reduction) scales with dose. Participants who reached and stayed on 15 mg lost considerably more on average than those on lower doses.

That said, the prescriber's job is to find the highest dose you tolerate well, not simply the highest dose. If side effects such as nausea are a concern at a particular step, slowing the pace is clinically sensible. More on what to expect as doses increase, including the stomach discomfort some people notice, is covered on the Mounjaro and stomach discomfort page.

In practice, most of the visible abdominal change people notice happens over several months. Patience matters: the biggest reductions in waist circumference in SURMOUNT-1 accumulated steadily across the full 72-week period rather than arriving in a rush in the first month. A practical guide to optimising fat loss on Mounjaro covers the lifestyle factors (protein intake, resistance activity, sleep) that the trial's background diet-and-exercise programme included alongside the medicine.

Who can access Mounjaro for weight management, and what should you do next?

Mounjaro is licensed in the UK for adults with a BMI of 30 or above, or a BMI from 27 upward with at least one weight-related condition such as high blood pressure, type 2 diabetes, high cholesterol or obstructive sleep apnoea. Lower thresholds can apply for some ethnic backgrounds under UK guidance. BMI alone does not guarantee suitability; the prescriber weighs the full clinical picture, including your medical history and any medicines you already take.

A broader look at how private treatment works (and what an NHS route involves) is on the Mounjaro overview page. If cost is a consideration, the Mounjaro price comparison explains what private treatment typically costs in the UK and what a legitimate price includes. More detail on the full range of weight-management options available through a clinical service is on the weight-loss treatment overview.

If you think Mounjaro could be right for you, the sensible next step is a clinical consultation. At nume, every consultation is read by a GPhC-registered prescriber on the same day, a real clinician, not an automated system. Check your eligibility and let our clinical team take it from there.